KEGG   PATHWAY: dro05235
Entry
dro05235                    Pathway                                
Name
PD-L1 expression and PD-1 checkpoint pathway in cancer - Desmodus rotundus (common vampire bat)
Description
Programmed cell death 1 (PD1) and its ligand (PDL1) are key regulatory physiological immune checkpoints that maintain self-tolerance in the organism by regulating the degree of activation of T and B  cells amongst other immune cell types. In solid tumors, the PD-1/PD-L1 inhibitory pathway can be (mis-)used to silence the immune system by increasing the expression of PD-L1 on the tumor cell surface. Up-regulation of PD-L1 is caused by activation of pro-survival pathways MAPK and PI3K/Akt as well as transcriptional factors HIF-1, STAT3 and NF-kappa B. The MAPK and PI3K signalling pathways are activated by gene mutations and growth factors. PD-L1 on tumor cells may then engage the PD-1 receptors resulting in suppression of T-cell mediated immune response. Therapeutic antibodies blocking the PD-1/PD-L1 pathway by targeting PD-L1 or PD-1 are highly effective in rescuing T cell anti-tumor effector functions.
Class
Human Diseases; Cancer: overview
Pathway map
dro05235  PD-L1 expression and PD-1 checkpoint pathway in cancer
dro05235

Organism
Desmodus rotundus (common vampire bat) [GN:dro]
Gene
112311145  HIF1A; hypoxia-inducible factor 1-alpha [KO:K08268]
112296254  EGF; pro-epidermal growth factor isoform X1 [KO:K04357]
112306912  EGFR; epidermal growth factor receptor [KO:K04361] [EC:2.7.10.1]
112317099  HRAS; GTPase HRas isoform X1 [KO:K02833]
112318275  KRAS; LOW QUALITY PROTEIN: GTPase KRas [KO:K07827]
112304041  LOW QUALITY PROTEIN: GTPase KRas-like [KO:K07827]
112313707  NRAS; GTPase NRas [KO:K07828]
112301126  RAF1; RAF proto-oncogene serine/threonine-protein kinase isoform X1 [KO:K04366] [EC:2.7.11.1]
112311345  MAP2K1; dual specificity mitogen-activated protein kinase kinase 1 [KO:K04368] [EC:2.7.12.2]
112312483  MAP2K2; dual specificity mitogen-activated protein kinase kinase 2 [KO:K04369] [EC:2.7.12.2]
112304801  MAPK3; mitogen-activated protein kinase 3 [KO:K04371] [EC:2.7.11.24]
112301746  MAPK1; mitogen-activated protein kinase 1 [KO:K04371] [EC:2.7.11.24]
112311412  FOS; proto-oncogene c-Fos [KO:K04379]
112314642  JUN; LOW QUALITY PROTEIN: transcription factor AP-1 [KO:K04448]
112297965  EML4; echinoderm microtubule-associated protein-like 4 [KO:K15420]
112298036  ALK; ALK tyrosine kinase receptor [KO:K05119] [EC:2.7.10.1]
112321016  PIK3R1; phosphatidylinositol 3-kinase regulatory subunit alpha isoform X1 [KO:K02649]
112305224  PIK3R2; phosphatidylinositol 3-kinase regulatory subunit beta [KO:K02649]
112314466  phosphatidylinositol 3-kinase regulatory subunit gamma [KO:K02649]
112310002  PIK3CB; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform isoform X1 [KO:K00922] [EC:2.7.1.153]
112299448  PIK3CD; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform [KO:K00922] [EC:2.7.1.153]
112307667  PIK3CA; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [KO:K00922] [EC:2.7.1.153]
112307354  PTEN; phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN [KO:K01110] [EC:3.1.3.16 3.1.3.48 3.1.3.67]
112311458  AKT1; RAC-alpha serine/threonine-protein kinase isoform X1 [KO:K04456] [EC:2.7.11.1]
112318919  AKT3; RAC-gamma serine/threonine-protein kinase [KO:K04456] [EC:2.7.11.1]
112320130  AKT2; RAC-beta serine/threonine-protein kinase [KO:K04456] [EC:2.7.11.1]
112299108  MTOR; serine/threonine-protein kinase mTOR isoform X1 [KO:K07203] [EC:2.7.11.1]
112316527  RPS6KB1; ribosomal protein S6 kinase beta-1 isoform X1 [KO:K04688] [EC:2.7.11.1]
112317229  RPS6KB2; ribosomal protein S6 kinase beta-2 [KO:K04688] [EC:2.7.11.1]
112300474  CHUK; LOW QUALITY PROTEIN: inhibitor of nuclear factor kappa-B kinase subunit alpha [KO:K04467] [EC:2.7.11.10]
112321547  IKBKB; inhibitor of nuclear factor kappa-B kinase subunit beta isoform X1 [KO:K07209] [EC:2.7.11.10]
112296261  IKBKG; NF-kappa-B essential modulator isoform X1 [KO:K07210]
112296519  NFKBIA; NF-kappa-B inhibitor alpha [KO:K04734]
112320245  NFKBIB; NF-kappa-B inhibitor beta [KO:K02581]
112302226  NFKBIE; NF-kappa-B inhibitor epsilon [KO:K05872]
112317867  NFKB1; nuclear factor NF-kappa-B p105 subunit isoform X1 [KO:K02580]
112317202  RELA; transcription factor p65 [KO:K04735]
112319176  IFNG; interferon gamma [KO:K04687]
112297082  IFNGR1; interferon gamma receptor 1 [KO:K05132]
112308734  IFNGR2; interferon gamma receptor 2 [KO:K05133]
112309187  JAK1; tyrosine-protein kinase JAK1 [KO:K11217] [EC:2.7.10.2]
112299737  JAK2; tyrosine-protein kinase JAK2 [KO:K04447] [EC:2.7.10.2]
112307780  STAT1; signal transducer and activator of transcription 1-alpha/beta isoform X1 [KO:K11220]
112298562  STAT3; signal transducer and activator of transcription 3 isoform X1 [KO:K04692]
112312607  TLR2; toll-like receptor 2 [KO:K10159]
112306266  TLR4; toll-like receptor 4 isoform X1 [KO:K10160]
112309685  toll-like receptor 9 isoform X1 [KO:K10161]
112301793  TIRAP; toll/interleukin-1 receptor domain-containing adapter protein [KO:K05403]
112309628  MYD88; myeloid differentiation primary response protein MyD88 [KO:K04729]
112303407  TRAF6; TNF receptor-associated factor 6 isoform X1 [KO:K03175] [EC:2.3.2.27]
112322654  NFATC1; nuclear factor of activated T-cells, cytoplasmic 1 [KO:K04446]
112303992  NFATC2; nuclear factor of activated T-cells, cytoplasmic 2 [KO:K17332]
112300806  NFATC3; nuclear factor of activated T-cells, cytoplasmic 3 isoform X1 [KO:K17333]
112312662  TICAM1; TIR domain-containing adapter molecule 1 [KO:K05842]
112307201  TIR domain-containing adapter molecule 2-like [KO:K05409]
112302711  CD274; programmed cell death 1 ligand 1 [KO:K06745]
112308039  PDCD1; programmed cell death protein 1 [KO:K06744]
112321823  PTPN6; tyrosine-protein phosphatase non-receptor type 6 isoform X1 [KO:K05697] [EC:3.1.3.48]
112310448  PTPN11; tyrosine-protein phosphatase non-receptor type 11 [KO:K07293] [EC:3.1.3.48]
112317041  BATF2; basic leucine zipper transcriptional factor ATF-like 2 [KO:K09034]
112311864  BATF; basic leucine zipper transcriptional factor ATF-like [KO:K09034]
112296620  BATF3; basic leucine zipper transcriptional factor ATF-like 3 isoform X1 [KO:K09034]
112303577  CSNK2A1; casein kinase II subunit alpha [KO:K03097] [EC:2.7.11.1]
112296650  CSNK2A2; casein kinase II subunit alpha' [KO:K03097] [EC:2.7.11.1]
112302356  CSNK2B; casein kinase II subunit beta [KO:K03115]
112322003  CD4; T-cell surface glycoprotein CD4 [KO:K06454]
112299317  LCK; tyrosine-protein kinase Lck isoform X1 [KO:K05856] [EC:2.7.10.2]
112314382  CD3E; LOW QUALITY PROTEIN: T-cell surface glycoprotein CD3 epsilon chain [KO:K06451]
112314387  CD3G; T-cell surface glycoprotein CD3 gamma chain [KO:K06452]
112321742  CD247; T-cell surface glycoprotein CD3 zeta chain [KO:K06453]
112314228  CD3D; T-cell surface glycoprotein CD3 delta chain [KO:K06450]
112315209  tyrosine-protein kinase ZAP-70 isoform X1 [KO:K07360] [EC:2.7.10.2]
112316249  MAP3K3; mitogen-activated protein kinase kinase kinase 3 [KO:K04421] [EC:2.7.11.25]
112308621  MAP2K3; dual specificity mitogen-activated protein kinase kinase 3 [KO:K04432] [EC:2.7.12.2]
112316519  MAP2K6; dual specificity mitogen-activated protein kinase kinase 6 [KO:K04433] [EC:2.7.12.2]
112302047  MAPK14; mitogen-activated protein kinase 14 isoform X1 [KO:K04441] [EC:2.7.11.24]
112321896  MAPK12; mitogen-activated protein kinase 12 [KO:K04441] [EC:2.7.11.24]
112302140  MAPK13; mitogen-activated protein kinase 13 [KO:K04441] [EC:2.7.11.24]
112322057  mitogen-activated protein kinase 11-like [KO:K04441] [EC:2.7.11.24]
112304844  LAT; LOW QUALITY PROTEIN: linker for activation of T-cells family member 1 [KO:K07362]
112303845  PLCG1; 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 isoform X1 [KO:K01116] [EC:3.1.4.11]
112305449  PPP3CB; serine/threonine-protein phosphatase 2B catalytic subunit beta isoform isoform X1 [KO:K04348] [EC:3.1.3.16]
112317863  PPP3CA; serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform [KO:K04348] [EC:3.1.3.16]
112305248  PPP3CC; serine/threonine-protein phosphatase 2B catalytic subunit gamma isoform isoform X1 [KO:K04348] [EC:3.1.3.16]
112297858  PPP3R1; calcineurin subunit B type 1 [KO:K06268]
112304508  PPP3R2; calcineurin subunit B type 2 [KO:K06268]
112311978  RASGRP1; RAS guanyl-releasing protein 1 isoform X1 [KO:K04350]
112307972  CD28; T-cell-specific surface glycoprotein CD28 [KO:K06470]
112320743  PRKCQ; protein kinase C theta type isoform X1 [KO:K18052] [EC:2.7.11.13]
Compound
C00076  Calcium cation
C00165  Diacylglycerol
C01245  D-myo-Inositol 1,4,5-trisphosphate
C05981  Phosphatidylinositol-3,4,5-trisphosphate
Reference
  Authors
Kythreotou A, Siddique A, Mauri FA, Bower M, Pinato DJ
  Title
PD-L1.
  Journal
J Clin Pathol 71:189-194 (2018)
DOI:10.1136/jclinpath-2017-204853
Reference
  Authors
Zhou TC, Sankin AI, Porcelli SA, Perlin DS, Schoenberg MP, Zang X
  Title
A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
  Journal
Urol Oncol 35:14-20 (2017)
DOI:10.1016/j.urolonc.2016.10.004
Reference
  Authors
Wang Y, Wang H, Yao H, Li C, Fang JY, Xu J
  Title
Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion.
  Journal
Front Pharmacol 9:536 (2018)
DOI:10.3389/fphar.2018.00536
Reference
  Authors
Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, Wu X, Ma J, Zhou M, Li X, Li Y, Li G, Xiong W, Guo C, Zeng Z
  Title
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape.
  Journal
Mol Cancer 18:10 (2019)
DOI:10.1186/s12943-018-0928-4
Reference
  Authors
Bardhan K, Anagnostou T, Boussiotis VA
  Title
The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation.
  Journal
Front Immunol 7:550 (2016)
DOI:10.3389/fimmu.2016.00550
Reference
  Authors
Shi Y
  Title
Regulatory mechanisms of PD-L1 expression in cancer cells.
  Journal
Cancer Immunol Immunother 67:1481-1489 (2018)
DOI:10.1007/s00262-018-2226-9
Reference
  Authors
Zerdes I, Matikas A, Bergh J, Rassidakis GZ, Foukakis T
  Title
Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations.
  Journal
Oncogene 37:4639-4661 (2018)
DOI:10.1038/s41388-018-0303-3
Reference
  Authors
Chen J, Jiang CC, Jin L, Zhang XD
  Title
Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
  Journal
Ann Oncol 27:409-16 (2016)
DOI:10.1093/annonc/mdv615
Reference
  Authors
Glodde N, Holzel M
  Title
RAS and PD-L1: A Masters' Liaison in Cancer Immune Evasion.
  Journal
Immunity 47:1007-1009 (2017)
DOI:10.1016/j.immuni.2017.12.001
Reference
  Authors
Ritprajak P, Azuma M
  Title
Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma.
  Journal
Oral Oncol 51:221-8 (2015)
DOI:10.1016/j.oraloncology.2014.11.014
Reference
  Authors
Nirschl CJ, Drake CG
  Title
Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy.
  Journal
Clin Cancer Res 19:4917-24 (2013)
DOI:10.1158/1078-0432.CCR-12-1972
Reference
  Authors
Saeidi A, Zandi K, Cheok YY, Saeidi H, Wong WF, Lee CYQ, Cheong HC, Yong YK, Larsson M, Shankar EM
  Title
T-Cell Exhaustion in Chronic Infections: Reversing the State of Exhaustion and Reinvigorating Optimal Protective Immune Responses.
  Journal
Front Immunol 9:2569 (2018)
DOI:10.3389/fimmu.2018.02569
Reference
  Authors
Sharpe AH, Pauken KE
  Title
The diverse functions of the PD1 inhibitory pathway.
  Journal
Nat Rev Immunol 18:153-167 (2018)
DOI:10.1038/nri.2017.108
Reference
  Authors
Boussiotis VA
  Title
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.
  Journal
N Engl J Med 375:1767-1778 (2016)
DOI:10.1056/NEJMra1514296
Reference
  Authors
Arasanz H, Gato-Canas M, Zuazo M, Ibanez-Vea M, Breckpot K, Kochan G, Escors D
  Title
PD1 signal transduction pathways in T cells.
  Journal
Oncotarget 8:51936-51945 (2017)
DOI:10.18632/oncotarget.17232
Reference
  Authors
Zuazo M, Gato-Canas M, Llorente N, Ibanez-Vea M, Arasanz H, Kochan G, Escors D
  Title
Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy.
  Journal
Ann Transl Med 5:385 (2017)
DOI:10.21037/atm.2017.06.11
Reference
  Authors
Patsoukis N, Li L, Sari D, Petkova V, Boussiotis VA
  Title
PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2.
  Journal
Mol Cell Biol 33:3091-8 (2013)
DOI:10.1128/MCB.00319-13
Reference
  Authors
Chinai JM, Janakiram M, Chen F, Chen W, Kaplan M, Zang X
  Title
New immunotherapies targeting the PD-1 pathway.
  Journal
Trends Pharmacol Sci 36:587-95 (2015)
DOI:10.1016/j.tips.2015.06.005
Reference
  Authors
Ok CY, Young KH
  Title
Targeting the programmed death-1 pathway in lymphoid neoplasms.
  Journal
Cancer Treat Rev 54:99-109 (2017)
DOI:10.1016/j.ctrv.2017.01.009
Related
pathway
dro04010  MAPK signaling pathway
dro04020  Calcium signaling pathway
dro04066  HIF-1 signaling pathway
dro04151  PI3K-Akt signaling pathway
dro04514  Cell adhesion molecules
dro04620  Toll-like receptor signaling pathway
dro04660  T cell receptor signaling pathway
KO pathway
ko05235   
LinkDB

DBGET integrated database retrieval system